DOSSIET
Written by
in
The agency cited Teva’s continuing supply problems as well as those of other drug makers struggling to fill the gap.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Leave a Reply